Business Wire

Children and young people encounter multiple forms of gender-based violence – an online course produced by an international project coordinated by Tampere University helps to identify and prevent it

24.1.2022 13:05:00 EET | Business Wire | Press release

Share

Children and young people are exposed to a wide range of gendered violence. However, the phenomenon is poorly understood, which makes helping the victims difficult. The international Education and Raising Awareness in Schools to Prevent and Encounter Gender-Based Violence (EraseGBV) project, coordinated by Tampere University, produced an online course to help identify, prevent and address gender-based violence.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220124005334/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

“Gender-based violence against children and youths is a little-known phenomenon. A better understanding of the issue by professionals working with children and young people is key to identifying violence and its consequences,” says Associate Professor Marita Husso from Tampere University. (Photo: Business Wire)

How do you approach young people who experience discrimination based on their gender expression? How do you deal with offensive images of your student, for example, on social media? And how do you address sexual violence faced by children or young people? Violence against children and youths is often referred to as bullying, even when it is considered assault by the Criminal Code.

“Gender-based violence against children and youths is a little-known phenomenon. A better understanding of the issue by professionals working with children and young people is key to identifying violence and its consequences,” says Associate Professor Marita Husso from Tampere University.

Husso leads the international Education and Raising Awareness in Schools to Prevent and Encounter Gender-Based Violence (EraseGBV) project coordinated by Tampere University, which has just published a free online course on encountering gender-based violence at schools in English, Finnish and Swedish. The training is also produced in Croatian, Spanish and Catalan.

It is a research-based e-learning package that develops new skills for those working in education, social work and health services. The training is aimed specifically at professionals working with 13–19-year-old teenagers but is also suitable for use with younger and older students. The training looks at the phenomenon from the perspectives of the person experiencing violence, the perpetrator, bystanders, and professionals and experts.

Schools play a pivotal role

Schools play a key role in identifying and addressing violence. The social environment of schools provides an opportunity to learn interaction skills and offers a unique opportunity to influence the perceptions and behaviour of children and young people. At the same time, it enables awareness-raising and change towards more equal relationships and more ethical practices.

“Addressing violence is a prerequisite for promoting equality and sustainable development. This new online training provides tools for preventing, identifying, and addressing violence. It provides information on such issues as digital violence, the impact of violence, good practices and legislation on the subject," says Husso.

“Getting help for problems of violence depends on the problem first being identified and addressed,” she emphasises.

The EraseGBV project has researched gender-based violence and ethical agency in schools and education in Finland, Croatia and Spain. The research partners comprise Tampere University; the University of Zagreb; Blanquerna Ramón Llull University; the Centre for Education, Counselling and Research (CESI); and Conexus.

For more information and instructions on how to register, please see the link to further information and the online course: https://projects.tuni.fi/erasegbv/training-programme/

Photo: In her future projects, Associate Professor Marita Husso will focus on promoting nonviolence and sustainable wellbeing and exploring harmful ideological, institutional and affective practices related to violence. Photo by Hanna-Kaisa Hämäläinen

Tampere University

The multidisciplinary Tampere University is the second largest university in Finland. The spearheads of our research and learning are technology, health, and society. The University is committed to addressing the greatest challenges that are facing our society and creating new opportunities. Almost all the internationally recognised fields of study are represented at the University. Together, Tampere University and Tampere University of Applied Sciences comprise the Tampere Universities community made up of more than 30,000 students and close to 5,000 employees. www.tuni.fi/en

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Enquiries:
Associate Professor Marita Husso
Faculty of Social Sciences, Tampere University
marita.husso@tuni.fi, tel. +358503182510

University Researcher Satu Lidman
Faculty of Social Sciences, Tampere University
satu.lidman@tuni.fi

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye